What are the fundraising trends in the longevity market?
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
The longevity market raised $7.5 billion across 107 deals between 2022 and 2025, with cellular reprogramming companies capturing over half of all capital.
2022 saw the largest single year thanks to Altos Labs' historic $3 billion raise, while 2025 marked the sector's maturation with Retro Biosciences' $1 billion Series A and Eli Lilly's first longevity investment.
Investors are now treating aging as a legitimate therapeutic target, not a fringe science experiment.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
Insights
- Khosla Ventures participated in at least 10 longevity deals across 2022-2025, making them the most active institutional investor in the healthspan sector by a wide margin.
- The top single deal each year captured between 16% and 72% of annual funding, showing that longevity investment remains highly concentrated around a few breakthrough companies.
- Cellular reprogramming companies raised over $4.5 billion across the four years, representing roughly 60% of all longevity market funding and validating epigenetic rejuvenation as the dominant scientific thesis.
- Average deal size jumped from $20 million in 2023 to $69 million in 2025, signaling that longevity has graduated from early-stage experimentation to institutional-grade investment rounds.
- Zero deals below $2 million closed in 2024, suggesting the longevity market has moved past angel-stage funding into professional venture territory.
- Big pharma entered the longevity market in 2025 when Eli Lilly invested in NewLimit and AbbVie Ventures led Oisin Biotechnologies' Series A in 2024.
- Consumer longevity platforms attracted celebrity investors like Kim Kardashian, Kevin Hart, and Paris Hilton in 2025, indicating mainstream cultural acceptance of healthspan optimization.
- European longevity companies raised approximately 15% of total funding, with Switzerland, UK, and Finland emerging as secondary hubs behind the dominant US market.
- AI integration became table stakes by 2025, with every major funded company deploying machine learning for drug discovery, diagnostics, or personalized health recommendations.
- Government funding entered the longevity sector meaningfully through Thymmune's $37 million ARPA-H grant in 2023 and multiple CIRM grants, signaling potential future public sector involvement.
First, how do we define the longevity market?
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
This is also the definition we use in our pitch about the longevity market.
In our longevity market deck, we have designed useful charts to give you full market clarity
How has funding activity in the longevity market changed over time?
2022 was the most active year by far with $4.15 billion raised, though this was almost entirely driven by Altos Labs' record-breaking $3 billion Series A, which alone represented 72% of that year's total.
2023 was the quietest year with only $421 million raised across 21 deals, as the broader biotech funding winter hit longevity companies hard and no mega-rounds materialized.
Compared to 2024's $1.24 billion, funding in 2025 increased by 40%. Looking back further, 2025 funding was 4 times higher than 2023's $421 million, though still 58% below 2022's outlier year.
If you exclude the top 1-2 deals each year, the underlying trend shows steady growth: the "base" longevity market grew from roughly $350 million in 2022 to approximately $550 million in 2025, with healthy mid-tier deal flow across therapeutics and diagnostics.
If you're interested in this industry, please note that we regularly keep in touch and share funding updates for this market on this page, which we keep continuously updated.
We also make quarterly analyses of the funding activity in the longevity market here.
| Year | Number of Deals | Total Raised | Comment |
|---|---|---|---|
| 2022 | 37 | $4.15B | Altos Labs' $3 billion raise made this year an outlier, representing 72% of total funding. Cellular reprogramming emerged as the dominant investment thesis with four major deals. |
| 2023 | 21 | $421M | The biotech funding winter hit longevity hard, with no mega-rounds closing. Viome's $86.5 million Series C was the largest deal, showing defensive positioning toward revenue-generating companies. |
| 2024 | 24 | $1.24B | BioAge Labs' IPO raised $198 million, proving public market appetite for longevity therapeutics. OURA's $200 million round showed consumer longevity had matured into a real category. |
| 2025 | 25 | $1.73B | Retro Biosciences' $1 billion Series A dominated the year. Eli Lilly's investment in NewLimit signaled big pharma now views aging as a legitimate therapeutic target. |
In our longevity market deck, we help you understand how the market is structured
Which startups in the longevity market raised the largest rounds over the last few years?
These startups raised the most over the last years in the longevity market:
- Altos Labs raised $3 billion in January 2022 because Jeff Bezos and Yuri Milner bet big on cellular reprogramming, recruiting Nobel laureates to build the largest longevity research organization ever funded.
- Retro Biosciences raised $1 billion in January 2025 because Sam Altman doubled down on his original $180 million seed bet, funding clinical trials for three drugs targeting autophagy and stem cells.
- Freenome raised $290 million from Roche in January 2022 because early cancer detection directly extends healthy lifespan, and Roche wanted strategic access to their multiomics blood testing platform.
- DELFI Diagnostics raised $225 million in July 2022 because their AI-based DNA fragmentomics can catch cancer at Stage 1, improving survival rates from 14% to over 90%.
- OURA raised $200 million in December 2024 because their smart ring became the leading longevity wearable, tracking biological age markers and sleep optimization for over 2.5 million users.
- BioAge Labs raised $198 million through their September 2024 IPO because public markets showed appetite for aging-focused therapeutics, validating their AI platform for metabolic aging drugs.
- Retro Biosciences raised $180 million in their April 2022 seed because Sam Altman personally funded the entire round to give the company runway through its first clinical proofs of concept.
- NewLimit raised $175 million across 2025 because Kleiner Perkins and Eli Lilly believed their mRNA-based liver rejuvenation therapy could reach clinical trials within two years.
- BioAge Labs raised $170 million in February 2024 because their partnership with Eli Lilly to combine their APJ agonist with Zepbound represented a credible path to the obesity market.
- Insilico Medicine raised $110 million in March 2025 because their AI drug discovery platform had already produced 20+ preclinical candidates and their lead fibrosis drug entered Phase 2 trials.
And, yes, we do cover most of them in our our beautiful pitch about the longevity market.
In our longevity market deck, we answer all the common questions from investors and entrepreneurs
Is the longevity market shifting toward smaller or bigger deals?
According to our own data, the average deal size across all four years in the longevity market was $70.5 million, though this number is heavily skewed by mega-rounds from Altos Labs and Retro Biosciences.
Breaking this down by year shows dramatic swings: 2022 averaged $112 million per deal (inflated by Altos), 2023 dropped to just $20 million during the biotech winter, 2024 recovered to $52 million, and 2025 reached $69 million. The longevity sector clearly follows broader biotech funding cycles, but with higher peaks due to billionaire-backed moonshots.
Excluding the top 1-2 outlier deals each year, the healthspan market shows a steadier trend of $15-25 million average deal sizes, suggesting the "core" longevity ecosystem is maturing with consistent Series A and B rounds for therapeutics companies.
| Year | Number of Deals | Average Deal Size | Deals Below $2M | Deals Above $50M |
|---|---|---|---|---|
| 2022 | 37 | $112.2M | 4 | 11 |
| 2023 | 21 | $20.0M | 1 | 3 |
| 2024 | 24 | $51.6M | 0 | 9 |
| 2025 | 25 | $69.3M | 2 | 6 |
| All Years | 107 | $70.5M | 7 | 29 |
In our longevity market deck, we identify repeatable patterns you can use if you’re building in this market
How concentrated was funding activity in the longevity market?
Funding concentration in the longevity market is extreme, with the top 10 deals capturing between 83% and 96% of capital each year. This pattern reflects a sector where investors make large bets on a handful of platform companies rather than spreading capital across many smaller plays.
The top single deal's share varied dramatically: Altos Labs captured 72% of 2022 funding, while OURA took just 16% of 2024's more distributed year. In 2025, Retro Biosciences' $1 billion round represented 58% of total longevity funding, showing that mega-rounds from cellular reprogramming companies continue to dominate healthspan investment.
| Year | Number of Deals | % by Top 1 | % by Top 3 | % by Top 10 |
|---|---|---|---|---|
| 2022 | 37 | 72.3% | 83.6% | 96.5% |
| 2023 | 21 | 20.6% | 53.9% | 91.3% |
| 2024 | 24 | 16.1% | 45.9% | 83.2% |
| 2025 | 25 | 57.7% | 74.2% | 95.3% |
| All Years | 107 | 39.8% | 57.0% | 78.2% |
In our longevity market deck, we track adoption trends and shifts in consumer behavior
Which categories in the longevity market received the most funding?
Cellular reprogramming and epigenetics captured approximately $4.7 billion (62% of all longevity funding) across the four years, driven by Altos Labs, Retro Biosciences, NewLimit, and Life Biosciences. Investors clearly believe that reversing cellular aging through epigenetic modification represents the highest-probability path to meaningful healthspan extension.
AI-powered drug discovery platforms raised approximately $480 million (6% of total), with Insilico Medicine, Juvenescence, and smaller players like Epiterna and Gero proving that machine learning can accelerate the identification of aging-related drug targets. This category benefits from lower capital requirements than traditional therapeutics while maintaining strong pharma partnership potential.
Early cancer detection and longevity diagnostics combined raised approximately $650 million (9% of total), led by Freenome and DELFI Diagnostics. These companies argue that catching cancer at Stage 1 is the most immediate way to extend healthy lifespan, with survival rates jumping from 14% to over 90% through early intervention.
| Category Name | Number of Deals | Total Raised | Startups and Amount |
|---|---|---|---|
| Cellular Reprogramming & Epigenetics | 12 | $4.7B | Altos Labs ($3B), Retro Biosciences ($1.18B), NewLimit ($320M), Life Biosciences ($82M), Turn Biotechnologies ($29M), Junevity ($20M) |
| Early Cancer Detection & Diagnostics | 8 | $650M | Freenome ($290M), DELFI Diagnostics ($225M), Viome ($154M), GlycanAge ($13M), Generation Lab ($11M) |
| AI Drug Discovery for Aging | 6 | $480M | Insilico Medicine ($205M), Juvenescence ($76M), BioAge Labs ($368M platform), Epiterna ($11M), Gero ($6M) |
In our longevity market deck, we have collected signals proving this market is hot right now
Who are the biggest investors in the longevity market?
Khosla Ventures is the most active institutional investor in the longevity market with at least 10 deals across 2022-2025, including lead positions in Turn Biotechnologies, Rejuvenation Technologies, Rubedo Life Sciences, and Circulate Health. Vinod Khosla has made aging a core investment thesis, backing both therapeutics companies and consumer longevity platforms.
Andreessen Horowitz Bio + Health participated in at least 4 major deals including BioAge Labs, Function Health, and Arda Therapeutics, bringing their consumer tech expertise to the longevity space. Their investment in Function Health with celebrity co-investors signaled mainstream acceptance of healthspan optimization.
Apollo Health Ventures backed 4 longevity companies across the period including Aeovian Pharmaceuticals, Cleara Biotech, and BE Therapeutics, specializing in therapeutics targeting core aging mechanisms like mTOR inhibition and senolytics.
VitaDAO participated in 4 deals including Turn Biotechnologies, Gero, Repair Biotechnologies, and Cyclarity Therapeutics, representing the emergence of decentralized science funding as a meaningful capital source for longevity research.
Kizoo Technology Capital led or participated in 4 deals in 2022 alone, including Revel Pharmaceuticals, Elastrin Therapeutics, and LIfT BioSciences, establishing themselves as a specialized European longevity investor.
Hevolution Foundation made impact investments in Aeovian Pharmaceuticals and Rubedo Life Sciences, deploying Saudi Arabian capital toward aging therapeutics as part of their mission to extend healthy human lifespan.
Disclaimer: this investor list may be incomplete; we focus on publicly disclosed lead and prominent recurring investors, so some frequent minority participants may be underrepresented. “Total funded” does not represent the amount personally invested by an individual investor. Instead, it refers to the aggregate amount raised across all fundraising rounds in which the investor participated.
| Investor | Number of Deals | Total Funded | Examples of startups |
|---|---|---|---|
| Khosla Ventures | 10+ | $300M+ | Viome, Turn Bio, Rejuvenation Technologies, Rubedo, BioAge, Loyal, NewLimit, Circulate Health, Neko Health |
| Apollo Health Ventures | 4 | $110M+ | Aeovian Pharmaceuticals, Cleara Biotech, BE Therapeutics, additional deals |
| VitaDAO | 4 | $45M+ | Turn Biotechnologies, Gero, Repair Biotechnologies, Cyclarity Therapeutics |
| Kizoo Technology Capital | 4 | $30M+ | Revel Pharmaceuticals, Elastrin Therapeutics, LIfT BioSciences, Cyclarity |
| Andreessen Horowitz | 4 | $280M+ | BioAge Labs, Function Health, Arda Therapeutics |
| Kleiner Perkins | 3 | $175M+ | NewLimit (Series A, Series B, Extension) |
| Hevolution Foundation | 3 | $75M+ | Aeovian Pharmaceuticals, Rubedo Life Sciences |
| Bold Capital Partners | 3 | $100M+ | Gameto, Viome, Deciduous Therapeutics |
| Longevitytech.fund | 4 | $20M+ | MitoRx Therapeutics, Cleara Biotech, Genflow Biosciences, Senisca |
| Sofinnova Investments | 3 | $270M+ | BioAge Labs, Aeovian Pharmaceuticals |
In our longevity market deck, we cover the latest tech updates shaping the market
What are the 2026 narratives around fundraising in the longevity market?
These are the dominant narratives shaping fundraising in the longevity market in 2025:
- Big pharma is finally entering longevity: Eli Lilly's investment in NewLimit and AbbVie's backing of Oisin signal that major drug companies now view aging as a legitimate therapeutic category, not fringe science.
- Cellular reprogramming has won the scientific debate: Over 60% of all longevity funding went to epigenetic rejuvenation companies, making it the consensus approach for extending healthy lifespan.
- AI integration is now mandatory: Every major funded longevity company uses machine learning for drug discovery, diagnostics, or personalized recommendations, and investors expect AI capabilities as table stakes.
- Celebrity capital is legitimizing consumer longevity: Kim Kardashian, Kevin Hart, and sports stars invested in Blueprint and Function Health, helping healthspan optimization reach mainstream cultural awareness.
- The $100+ million round is now common: Six longevity deals exceeded $50 million in 2025 alone, showing the sector has graduated from small experimental bets to institutional-scale investment rounds.
- Longevity clinics are scaling rapidly: Fountain Life, Human Longevity Inc., and Circulate Health are expanding clinic networks across the US, creating physical infrastructure for preventive healthspan medicine.
- Biological age testing has become a product category: Generation Lab, GlycanAge, and others raised meaningful rounds for diagnostics that measure how fast you're aging, not just if you're sick.
- European longevity is emerging as a secondary hub: Swiss, UK, and Finnish companies raised 15% of total funding, with Timeline, GlycanAge, and Cellular Origins proving the sector isn't exclusively American.
- Government funding is entering the picture: ARPA-H and CIRM grants to Thymmune and Rejuvenate Bio suggest public sector interest in longevity research may accelerate in coming years.
- The dog longevity market proved translational potential: Loyal's $45 million round showed that canine aging drugs can serve as a bridge to human therapies while generating near-term revenue.
In our longevity market deck, we will give you useful market maps and grids
Related blog posts
- What is the latest update in the longevity market?
- What are the latest news in the longevity market?
- What is the real market size of the longevity market?
- What are the latest funding news in the longevity market?
- Evolution of the funding activity in the longevity market
- Which startups have raised the most funding in the longevity market?
- What are the most valued startups in the longevity market?
